Eptinezumab
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Eptinezumab: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Eptinezumab is an anti-CGRP monoclonal antibody originally used for migraine prevention. The TxGNN model predicts it may be effective for migraine with brainstem aura, but there are currently no registered clinical trials and 10 publications, mostly indirect (post hoc analyses, reviews, case reports), supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine disorder (the Singapore licence has no indication text on record) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, eptinezumab is an anti-CGRP monoclonal antibody given by intravenous infusion. CGRP signalling is central to migraine pathophysiology, and its efficacy in migraine prevention has been established.
Brainstem aura is a migraine subtype, so it is closely related to the approved indication. A post hoc analysis of the PROMISE-1 and PROMISE-2 trials in patients with self-reported aura supports efficacy in aura-associated migraine. Case reports and a literature review also suggest anti-CGRP antibodies may help with aura.
There is an important caveat. A 2025 randomised controlled trial found that PACAP38-induced migraine attacks are independent of CGRP signalling, which suggests CGRP-targeted therapy may not work for every patient. No trial has specifically enrolled patients with brainstem aura.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35302389 | 2022 | Post hoc analysis of RCT | Cephalalgia | Efficacy and safety of eptinezumab in migraine patients with self-reported aura (PROMISE-1 and PROMISE-2) |
| 40229719 | 2025 | RCT | J Headache Pain | PACAP38-induced migraine attacks are independent of CGRP signalling |
| 35268319 | 2022 | Case reports and review | J Clin Med | Anti-CGRP antibodies may be useful for migraine aura |
| 40341526 | 2025 | Cohort/Genetic study | Headache | Two genetic conditions with prominent migraine responded to CGRP antagonist therapy |
| 30725283 | 2019 | Review | Handb Exp Pharmacol | Role of CGRP in migraine |
| 32699706 | 2020 | Review | Cureus | CGRP antagonists in episodic and chronic migraine |
| 33550872 | 2021 | Review | Pain Manag | Overview of new acute and preventive migraine treatments, including eptinezumab |
| 42090640 | 2026 | Cohort (safety) | Neurology | Glaucoma risk associated with CGRP inhibitors in migraine |
| 42390441 | 2026 | Cohort (safety) | Cephalalgia | Cerebrovascular risk with CGRP antibodies versus onabotulinumtoxinA |
| 40191903 | 2025 | Case report | Rev Neurol | Wearing-off effect managed with eptinezumab in chronic migraine refractory to two subcutaneous CGRP antibodies |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16325P | VYEPTI Concentrate for Solution for Infusion 100mg/ml | Infusion, solution concentrate | Not recorded in the compiled data |
Safety Considerations
Please refer to the package insert for safety information.
Observational studies compiled for this report raised questions about glaucoma and cerebrovascular (ischaemic stroke or TIA) risk with CGRP inhibitors. These are signals to consider in safety planning, not established conclusions. No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is mechanistically sensible, since brainstem aura is a migraine subtype, and eptinezumab is already marketed in Singapore. However, the supporting evidence is indirect (post hoc analyses, reviews, case reports), no trial has enrolled brainstem aura patients, and package insert safety data are missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, to allow safety screening
- Detailed mechanism of action data
- Prospective or subgroup data specifically in brainstem aura patients
- Review of the cerebrovascular and glaucoma safety signals in this population
- Clarification of the approved indication text for the Singapore licence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.